Deep Sequencing Test for Intraocular Infections
(OPTICS Trial)
Trial Summary
The trial protocol does not specify whether you need to stop taking your current medications.
Research shows that Metagenomic Deep Sequencing (MDS) can accurately detect pathogens in eye fluid samples, which helps in diagnosing infections more effectively than traditional methods.
12345The research articles focus on the effectiveness of metagenomic deep sequencing (mNGS) in diagnosing intraocular infections, but they do not provide specific safety data for humans. However, these studies do not report any safety concerns related to the use of mNGS in humans.
12367Metagenomic Deep Sequencing (MDS) is unique because it uses advanced genetic sequencing to identify a wide range of pathogens in eye infections, which can be difficult to diagnose with traditional methods. This approach allows for a more accurate and comprehensive detection of bacteria, viruses, fungi, and parasites in intraocular fluid, potentially leading to better-targeted treatments.
12389Eligibility Criteria
This trial is for adults over 18 with suspected infectious uveitis or post-operative endophthalmitis, which are types of eye infections. It's not suitable for those who can't consent, don't have enough specimen for MDS testing, are under 18, or are pregnant.Inclusion Criteria
Exclusion Criteria
Trial Timeline
Screening
Participants are screened for eligibility to participate in the trial
Randomization and Initial Follow-up
Participants are randomized to receive MDS testing results or not, followed by initial follow-up visits
Follow-up
Participants are monitored for safety and effectiveness after randomization